NutriPATH PATHOLOGY • PATIENT REPORT
16 Harker St, Burwood VIC, 3125 • info@nutripath.com.au • 1300 688 522

26115-0015

Dr Test Doctor (Test Doctor) Test Clinic. 123 Test Street, Test Suburb Victoria 3125

Lab ID
Patient ID P000060
Ext ID 26115-0015

Test Patient

Sex: Female • 56yrs • 01-Jan-70
123 Home Street, Test Suburb VIC 3125

RECEIVED
25-Apr-26

Clinical Notes .

LIPOSCREEN & OXIDISED LDL

Specimen type - Blood-Serum

Collected
15-Apr-26

LIPID STUDIES

TEST	RESULT	H/L	REFERENCE	UNITS
Cholesterol	5.5	H	(<5.5)	mmol/L
Triglycerides	2.2	H	(<2.0)	mmol/L
HDL (Protective)	1.1		(1.0-2.2)	mmol/L
Non-HDL Cholesterol	4.4	H	(<4.0)	mmol/L
LDL-C (Atherogenic)	3.4	H	(<3.0)	mmol/L
Cholesterol/HDLC Ratio	5.0	H	(<5.0)	ratio
LDL/HDL Ratio	2.0		(<3.2)	ratio
Trig/HDL Ratio	2.0	H	(0.5-1.7)	ratio

SPECIFIC LIPOPROTEINS

TEST	RESULT	H/L	REFERENCE	UNITS
Lipoprotein (a)	14.6		(<75.0)	nmol/L
Oxidised LDL	77.0	H	(<70.0)	U/L

LIPOSCREEN, LDL Subfractions

TEST	RESULT	H/L	REFERENCE	UNITS
Very Low Density Lipoprotein (VLDL)	0.98	H	(<0.60)	mmol/L
Mid Density Lipoprotein (IDL-1)	0.39		(<0.60)	mmol/L
Mid Density Lipoprotein (IDL-2)	0.26		(<0.40)	mmol/L
Mid Density Lipoprotein (IDL-3)	0.31		(<0.60)	mmol/L
Low Density Lipoprotein (LDL-1)	0.88		(<1.50)	mmol/L
Low Density Lipoprotein (LDL-2)	1.06	H	(<0.80)	mmol/L
Low Density Lipoprotein (LDL-3)	0.44	H	(<0.20)	mmol/L
Low Density Lipoprotein (LDL-4)	0.03	H	(<0.01)	mmol/L
Low Density Lipoprotein (LDL-5)	0.00		(<0.01)	mmol/L
Low Density Lipoprotein (LDL-6)	0.00		(<0.01)	mmol/L
Low Density Lipoprotein (LDL-7)	0.00		(<0.01)	mmol/L
Mean Particle Size	263	L	(>268)	Angstrom

LDL Phenotype Pattern Type B - ABNORMAL

SAMPLE REPORT

NATA Accreditation No. 20770. The current scope of accreditation is available on the NATA website.

Dr Test Doctor (Test Doctor) Test Clinic. 123 Test Street, Test Suburb Victoria 3125

Lab ID
Patient ID P000060
Ext ID 26115-0015

Test Patient

Sex: Female • 56yrs • 01-Jan-70
123 Home Street, Test Suburb VIC 3125

RECEIVED
25-Apr-26



Lipids Comment:

The National Vascular Disease Prevention Alliance (NVDPA) treatment target levels for high risk people are:

Total Cholesterol <4.0 mmol/L
Fasting Triglycerides < 2.0 mmol/L
Non-HDL Cholesterol <2.5 mmol/L
HDL-Cholesterol >=1.00 mmol/L
LDL-Cholesterol <2.0 mmol/L

Increased non-HDL Cholesterol is a significant marker for subclinical atherosclerosis (ref: Cardiology Today 2013; 3(2): pp25-27).

LDL-C COMMENT:

Low levels of HDL cholesterol and high levels of LDL cholesterol are associated with an increased risk of atherosclerotic vascular disease. A LDL Subfractions test may be considered to determine the presence of small, dense (highly atherogenic) LDLs which are a primary cause of Coronary Artery Disease (CAD). The LDL subtypes are not detectable through conventional Lipid Profiles.

Lipoproteins Comment:

ELEVATED OXIDISED LDL LEVEL:

Raised Oxidised LDL levels occur from many causes including smoking, poor blood sugar level control, diets high in trans fat and diets poor in antioxidants. Elevated Oxidised levels are also seen more frequently in diabetic patients than non-diabetics.

Liposcreen LDL Subfractions

The Liposcreen LDL Subfractions test provides a superior indicator for Coronary Artery Disease (CAD) risk than other conventionally available lipid profiles.

Many individuals with normal LDL and HDL cholesterol levels remain at risk from CAD, as these conventional tests do not convey the detail of the CAD risk.

Liposcreen additionally quantifies the different LDL subfractions.

LDL Phenotype Pattern:

This patient has a LDL profile Not indicative of Type A, which is deemed **ABNORMAL**.

SAMPLE REPORT

NATA Accreditation No. 20770. The current scope of accreditation is available on the NATA website.

Dr Test Doctor (Test Doctor) Test Clinic. 123 Test Street, Test Suburb Victoria 3125

Lab ID
Patient ID P000060
Ext ID 26115-0015

Test Patient

Sex: Female • 56yrs • 01-Jan-70
123 Home Street, Test Suburb VIC 3125

RECEIVED
25-Apr-26

This pattern is due to the presence of elevated levels of small dense LDLs (LDL3 – LDL7) and/or a low Mean LDL Particle Size result.

Type B (Patient may have some or all of the below present)

Deemed an ABNORMAL profile.

Predominance of small/dense (more atherogenic) LDL subclasses (LDL3, 4, 5, 6, 7).

Mean Particle Size of < 258 Angstrom (A).

Raised Cholesterol, Raised Triglycerides, Raised VLDL, Low HDLC

This profile is the designated atherogenic lipoprotein phenotype, consistent with an increased risk of CAD.

It is also characteristically prevalent in insulin-resistant states such as Metabolic Syndrome and Type 2 Diabetes mellitus.

Mean LDL Particle Size:

The LDL Mean Particle size is borderline, which may indicate the presence of LDLs of a size capable of penetrating the endothelial lining and causing the development of atheromatous plaques.

Follow up/Review Timeframe:

Follow up Liposcreen testing, for this patient, is recommended in 6 months.

Methodology

Automated Chemistry/Immunochemistry, Gel Electrophoresis

SAMPLE REPORT

NATA Accreditation No. 20770. The current scope of accreditation is available on the NATA website.